1-5 of 5
Robert Zerbib
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial

Norbert Vey, Pierre-Yves Dumas, MD, Christian Recher, MD PhD, Lauris Gastaud, MD, Bruno Lioure, MD, Claude-Eric Bulabois, MD, Cecile Pautas, Jean-Pierre Marolleau, MD PhD, Stéphane Leprêtre, MD, Emmanuel Raffoux, MD, Xavier Thomas, MD, Yosr Hicheri, Caroline Bonmati, MD, Bruno Quesnel, MD PhD, Philippe Rousselot, Sylvie Castaigne, MD PhD, Eric Jourdan, MD, Jean Valère Malfuson, Gaelle Guillerm, MD, Jean Henri Bouhris, Mario Ojeda, MD, Mathilde Hunault, MD PhD, Norbert Ifrah, MD PhD, Claude Gardin, MD PhD, Andre Delannoy, MD, Lucile Beautier, Carine Paturel, PhD, Pascale Andre, PhD, Robert Zerbib, Claude Preudhomme, PharmD, PhD, Antoine Toubert, MD PhD, Nicolas Dulphy, PhD, Daniel Olive, MD PhD, Arnaud Pigneux, MD, Herve Dombret, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 889.
https://doi.org/10.1182/blood.V130.Suppl_1.889.889
Published: 2017
Journal Articles

A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma

Don M. Benson, Jr., MD, PhD, Adam D Cohen, MD, Craig C Hofmeister, MD, Munshi C Nikhil, MD, Sundar Jagannath, MD, Yvonne A Efebera, MD, Gary Spitzer, MD, Robert Zerbib, Pascale Andre, PhD, Shawna Oxier, Michael A. Caligiuri, MD
Journal: Blood
Blood (2013) 122 (21): 3181.
https://doi.org/10.1182/blood.V122.21.3181.3181
Published: 2013
Journal Articles

Repeated Dosing Of Anti-KIR (IPH2101) As Maintenance Therapy In Ederly Patients With Acute Myeloid Leukemia

Norbert Vey, MD, Jean-Henri Bourhis, MD, PhD, Christian Recher, MD PhD, Anne Etienne, MD, Aude Charbonnier, MD, PhD, Pascale Andre, PhD, Jérôme Rey, MD, Franceline Calmels, Robert Zerbib, Renaud Buffet, MD, Thomas Prebet, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 2696.
https://doi.org/10.1182/blood.V122.21.2696.2696
Published: 2013
Journal Articles

A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results

Don M. Benson, Jr., MD, PhD, Adam D Cohen, MD, Nikhil C. Munshi, MD, Sundar Jagannath, MD, Gary Spitzer, MD, Craig C. Hofmeister, MD, Robert Zerbib, Pascale Andre, PhD, Yvonne A Efebera, M.D., Shawna Oxier, Michael A. Caligiuri, M.D.
Journal: Blood
Blood (2012) 120 (21): 4058.
https://doi.org/10.1182/blood.V120.21.4058.4058
Published: 2012
Journal Articles

OPTIMUM Dose of Thalidomide for Relapsed Multiple Myeloma.

Martin Kropff, Honorata Giongco Baylon, MD, Jens Hillengass, MD, Tadeusz Robak, Roman Hajek, MD, Peter Liebisch, MD, Stefan Goranov, MD, Cyrille Hulin, Joan Blade, Tomaso Caravita, Herve Avet-Loiseau, MD, PhD, Thomas M. Moehler, Claire Pattou, Lela Lucy, Elisabeth Kueenburg, Axel Glasmacher, MD, Robert Zerbib, Thierry Facon
Journal: Blood
Blood (2009) 114 (22): 959.
https://doi.org/10.1182/blood.V114.22.959.959
Published: 2009